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Genomic and personalized medicine have become buzz phrases that pervade all fields of medicine. Rapid advances
in ‘‘-omics’’ fields of research (chief of which are genomics, proteinomics, and epigenomics) over the last few years
have allowed us to dissect the molecular signatures and functional pathways that underlie disease initiation and
progression and to identify molecular profiles that help the classification of tumor subtypes and determine their
natural course, prognosis, and responsiveness to therapies. Genomic medicine implements the use of traditional
genetic information, as well as modern pangenomic information, with the aim of individualizing risk assessment,
prevention, diagnosis, and treatment of cancers and other diseases. It is of note that personalizing medical
treatment based on genetic information is not the revolution of the 21st century. Indeed, the use of genetic
information, such as human leukocyte antigen-matching for solid organ transplantation or blood transfusion based
on ABO blood group antigens, has been standard of care for several decades. However, in recent years rapid
technical advances have allowed us to perform high-throughput, high-density molecular analyses to depict the
genomic, proteinomic, and epigenomic make-up of an individual at a reasonable cost. Hence, the so-called genomic
revolution is more or less the logical evolution from years of bench-based research and bench-to-bedside
translational medicine.
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INTRODUCTION
Genomic medicine and personalized medicine have
become buzz phrases that pervade all fields of medicine.
The rapid advances in ‘‘–omics’’ research (chief of which are
genomics, proteinomics, and epigenomics) over the last few
years have allowed us to dissect the molecular signatures
and functional pathways that underlie disease initiation and
progression and to identify molecular profiles that help
the classification of tumor subtypes and determine their
natural course, prognosis, and responsiveness to therapies.
Genomic medicine implements the use of traditional genetic
information, as well as modern pangenomic information,
with the aim of individualizing risk assessment, prevention,
diagnosis, and treatment of cancers and other diseases.
It is of note that personalizing medical treatment based on
genetic information is not a revolution of the 21st century.
Indeed, the use of genetic information, such as human
leukocyte antigen-matching for solid organ transplantation
or blood transfusion based on ABO blood group antigens,
has been standard of care for several decades. However, in
recent years rapid technical advances have allowed us to
perform high-throughput, high-density molecular analyses
to describe the genomic, proteinomic, and epigenomic
make-up of an individual at a reasonable cost. Hence, the
so-called genomic revolution is more or less the logical
evolution from years of bench-based research and bench-to-
bedside translational medicine. The challenge is to deter-
mine how the structural changes, both within the germline
and soma, affect how genes globally interact within the
germline, how they interact locally between the germline
and tumor and, finally, how the environment and lifestyle
choices can alter genes at a functional level in order to
modulate thyroid cancer susceptibility, aggressiveness, and
the likelihood of cure.
Molecular testing for non-inherited genetic profiles (i.e.,
the somatic alteration of genes such as KIT, BRAF, and
EGFR) to tailor and optimize treatment approaches has
become implemented in the routine armament for the
diagnosis and treatment of various tumors (i.e., lung, colon,
breast, gastrointestinal stromal, thyroid, etc.) and will not be
discussed in this review (1–4). The impact on practicing
personalized medicine will be tremendous. For instance,
it will not be long before we can tailor our surgical approa-
ches and surveillance of patients with papillary micro-
carcinomas based on the BRAF (V600E) mutation status (5).
On the other hand, human disease susceptibility can be
seen as the result of either rare germline genetic variations
of high penetrance or as common genomic variants of low
penetrance. The latter path on the road to practicing genomic
medicine is using the technical advances of high-throughput,
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91high-density analyses (e.g., whole-genome linked analysis)
to correlate common genetic variations (e.g., single
nucleotide polymorphisms) to common diseases (6). In
this way, a vast variety of allelic alterations have been
identified that correlate with the risk of cancer, other
common diseases (e.g., diabetes, hypertension, autism,
obesity, etc.) or even a patient’s ability to respond to severe
sepsis (7–10). There is tremendous hype to push forward
on this path in order to implement ‘‘–omics’’-based
analyses into clinical practice (11,12). However, there are
some obstacles to clinical implementation that must not be
underestimated and the impact on public health must be
critically discussed (12–14). Beyond ethical and legal
issues, numerous studies have shown that susceptibility
variants for common diseases only marginally contribute
to the disease risk with odd ratios of around 1.5 (6). For
instance, in coronary heart syndrome, other medical
conditions and lifestyle factors, such as blood pressure,
d i a b e t e s ,o rs m o k i n g ,a r eb e t t e rp r e d i c t o r so fc a r d i o v a s -
cular events than are genomic variants (15). Furthermore,
easy access to affordable, high-volume sequencing/geno-
typing techniques (i.e., the ability to sequence thousands of
genes or millions of single nucleotide polymorphisms)
resulted in a flood of studies reporting the association of
one or another genetic variant to disease or disease
outcome (6). This harbors a profound statistical dilemma.
Among the major limitations of many association studies
is that they are profoundly underpowered. For instance, to
detect an association with an odds ratio of 1.5 (i.e., a
patient with the variant is 1.5 times more likely to have the
d i s e a s eo ro u t c o m e )m o r et h a n1 , 0 0 0p e o p l en e e dt ob e
tested when the suspected susceptibility variant occurs
with a frequency of 0.2 (20% of the population).
Furthermore, none of the technologies used today achieves
100% accuracy. Even if we propose a test accuracy of 99%
— to be more realistic, we should estimate it between
80% and 95% — at least one of 100 patients would receive
an erroneous result. Hence, there is the widely accepted
opinion that clinical implementation should be scrutinized
under the framework of analytic validity, clinical validity,
clinical utility, and ethical, legal, and social implications.
The last of these implies that for each test there has to be a
medical treatment available to prevent the outbreak or
influence the course of the disorder in those patients who
are identified as being at risk.
However, one can envision that using population-wide
‘‘–omics’’ screening methods should help to establish
which genetic changes, whether static (structural genomic)
or dynamic (expression profiling), predispose under which
environmental conditions to disrupt the usual cellular
balances of apoptosis, survival, and maintenance of differ-
entiation. In the future, this will provide us with unique
genetic signatures for the prediction of outcomes and
choices of therapy or prevention, or, in short, personalized
genomic healthcare. Furthermore, the field of pharmacoge-
nomics allows us to anticipate what the future can hold. For
instance the HCP5 single nucleotide polymorphism serves
as a predictor for a hypersensitivity to antiviral drug
medications, and the CYP2C19 variant is associated with a
diminished clopidogrel response (16,17). Hence, patients at
risk of adverse events or with limited response to medica-
tion can be identified using virtually ‘‘bed-side’’ genetic
testing methods and the treatment regimen can be tailored
accordingly.
PERSONALIZED MEDICINE FOR HERITABLE
ENDOCRINE NEOPLASIAS
This review will focus on the implementation of validated
personalized healthcare practices and the utilization of
evidence-based genetic tests for the individualized treat-
ment of inherited endocrine, especially thyroid, cancers.
Looking back in history, one finds that endocrine neoplasias
and those involved in their treatment have pioneered the
field of clinical cancer genetics and personalized medicine.
There is an array of heritable endocrine neoplasias for which
genes that connote a high degree of penetrance have been
identified and validated. In these situations, molecular
diagnostic and predictive testing leads to tailored surveil-
lance and clear therapeutic implications that, at best, allow
for preventive surgery.
MEN 2 and RET: the paradigm for the practice of
genomic medicine
The inherited tumor syndrome multiple endocrine neo-
plasia type 2 (MEN 2) can be considered the role model for
the practice of genomic medicine (4,18–20). MEN 2 is an
autosomal-dominant, transmitted tumor syndrome caused
by germline mutation in the RET (REarrangend during
Transfection) proto-oncogene and is comprised of the key
endocrine neoplasia components of pheochromocytoma,
hyperparathyroidism, and, importantly, medullary thyroid
carcinoma (MTC) as the life-limiting alteration (21,22).
About 25% of all MTCs occur as part of the autosomal-
dominant MEN 2 syndrome, hence all patients treated for
MTC should be tested for this mutation regardless of age or
known family history. The presence of the RET MTC
susceptibility gene enabled us to implement a powerful
molecular diagnostic test to identify mutation carriers at
premorbid stages (i.e., predictive testing) (Table 1). In this
situation, family members who are found to carry
the family-specific mutation but who are as yet unaffected
can be subjected to life-saving prophylactic surgery and
surveillance (18). Importantly, the delineation of a geno-
type-phenotype correlation allows us to tailor surgical
techniques based on the exact amino acids that are altered
(23). Furthermore, family members not harboring family-
specific disease-associated mutations can be definitively
Table 1 - Risk stratification in MEN 2.
Risk group Risk type RET codon Youngest patient Age for prophylactic surgery
1
3 Highest 922, 918, 883 9 months ,2 years
2a Very high 634, 630 12 months ,2 years
2b High 620, 618, 611, 609 5 years ,5 years
1 Low 891, 804, 791, 790, 768 6 to 22 years ,10 years
1Based on the youngest observed patient.
Personalized medicine for endocrine neoplasia
Dammann M and Weber F
CLINICS 2012;67(S1):91-97
92advised that they only have the same risk as the general
population of developing the component neoplasias of
MEN 2, so could be excluded from lifelong clinical
surveillance and prophylactic surgeries.
There are three forms of MEN 2. First, MEN 2A, the most
common form, is characterized by the components MTC:
primary hyperparathyroidism and pheochromocytoma.
Because MTC can show a high penetrance at a young age,
prophylactic surgery should be offered depending on the
risk genotype before the age of 5–10 years. MEN 2B is the
most aggressive form caused by germline mutations in
codon 918 (98%) or codon 883 (2%) and is associated with an
age of onset for MTC in the first year of life. Therefore,
genetic testing should be offered shortly after birth in order
to identify those infants who require early preventive
surgery. Of note, in MEN 2B MTC occurs together with
pheochromocytoma (50%) and marfanoid habitus (100%),
intestinal ganglioneuromatosis, mucosal neuromas, and
thickening of the corneal nerve (all up to 90%), but not
primary hyperparathyroidism. Familial MTC is often
considered a separate entity giving rise to MTC as the sole
clinical manifestation. Whether this holds true today has to
be critically discussed. Most likely, familial MTC is just the
result of variability in penetrance, thus surveillance for
hyperparathyroidism and pheochromocytoma should be
offered to these patients as well. Importantly, for the most
common exon 11 mutation (RET C634G), a penetrance of
21% by age 50 for hyperparathyroidism and 52% by age 30
and 83% by age 50 for pheochromocytoma have been
reported. However, it is not possible to predict precisely if
and when an individual patient might suffer from para-
thyroid hyperplasia or pheochromocytoma (24). Hence, all
patients should undergo lifelong surveillance. Furthermore,
there are other clinical aspects that cannot be entirely
explained by the traditional mutations in RET. For instance,
within some MEN 2 families, the age of onset and severity
of disease vary considerably among the affected family
members despite carrying identical germline RET muta-
tions. For example, for the most common exon 11 mutation
(Cys634Trp) the age of onset for MTC varies between
families from 3 years to .60 years. To what extent allelic
variants play a role is a matter of continued investigation
(25). For instance, the variant IVS1-126G . T in a large
family with the G533C mutation was associated with an
early onset of disease (26). One might envision that the
integration of classic Mendelian cancer predisposition genes
with genomic alterations of low penetrance might bring the
practice of personalized genomic medicine to the next level
(26,27).
Heritable adrenal neoplasias
Heritable adrenal neoplasias can affect the medulla
(pheochromocytoma) as well as the adrenal cortex. The
genetic differential diagnoses for adrenocortical neoplasia
are summarized in Table 2. Diagnostic work-up, manage-
ment, and surveillance of patients with hereditary diseases
can differ significantly from their sporadic counterparts, so
it is important to identify those patients. For instance, in
MEN 1, adrenocortical lesions occur in as many as 40% of
patients. Most manifest as non-functional, hyperplastic
lesions and present an indolent course. Although the
incidence of adrenocortical carcinoma has been reported
to be between 2% and 6%, there is no a consensus regarding
the management of MEN 1-associated adrenocortical
lesions. Even though there is no genotype-phenotype
correlation, it is a widely accepted protocol to surgically
remove lesions exceeding a cutoff size of 3 cm in diameter.
A considerable proportion of pheochromocytomas are
heritable and form part of tumor syndromes other than
MEN 2. In addition, studies have shown that pheochromo-
cytomas can precede the development of MTC, so knowl-
edge about differential diagnosis is important. Pheochromo-
cytomas can occur in the adrenal medulla but also extra-
adrenally in the head-and-neck region as well as being
abdominal and thoracic, where they are termed paragan-
glioma (PGL). It used to be thought that about 10% of all
pheochromocytomas occur in a familial setting and are
caused by germline genetic alterations. Today, there is
growing evidence that about 25–30% of all patients with
pheochromocytoma and paraganglioma harbor a germline
Table 2 - Genetic differential diagnosis for adrenocortical neoplasias.
Location Heritable tumor syndrome and phenotype Gene
Adrenocortical neoplasia + Multiple endocrine neoplasia type 1 (MEN 1)
Adrenocortical adenoma, HPT, pituitary and neuroendocrine tumors
+ Beckwith–Wiedemann syndrome (BWS)
ACC, Wilms’ tumor, hepatoblastoma, rhabdomyosarcoma
+ McCune–Albright syndrome
Cushing syndrome, pituitary tumors, polyostotic fibrous dysplasia, patchy skin
pigmentation, thyrotoxicosis, gigantism
+ Li–Fraumeni Syndrome (LFS)












Pheochromozytoma + Multiple endocrine neoplasia type 2 (MEN 2)
+ Von Hippel–Lindau disease (VHL)
+ Neurofibromatosis type 1 (NF1)





ACC: adrenocortical carcinoma. HPT: hyperparathyroidism.
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93mutation. Six tumor syndromes, including MEN 2, Von
Hippel–Lindau disease, neurofibromatosis (NF1) and pheo-
chromocytoma-paraganglioma syndrome (PGL1, PGL2 and
PGL3), and their predisposing genes have been identified
(Table 3). The predominant signs of neurofibromatosis type
1 include characteristic cafe ´-au-lait spots, neurofibromas,
and other lesions such as freckling of the skin. Although
penetrance of pheochromocytoma in NF1 is low (,5%),
malignant pheochromocytomas are not infrequent. In
patients with NF1 and pheochromocytoma there are no
mutation hot spots, instead the alterations are spread all
over the gene and include large deletions or rearrangements
in about 10% of patients. As outlined above, pheochromo-
cytoma in MEN 2 shows a variable penetrance that can be as
high as 50%. Most notably, mutations in codons 634 and
918 harbor a very high risk of developing this disease.
Pheochromocytomas in MEN 2 are commonly benign and
located bilaterally in the adrenal medulla. Von Hippel-
Lindau syndrome is an autosomal-dominant disorder that
predisposes individuals to pheochromocytoma and other
important neoplasias such as clear cell renal carcinomas,
pancreatic islet cell tumors, and cystic disease of the kidney
and pancreas. Interestingly, although the overall penetrance
of pheochromocytoma ranges between 20% and 30% of
patients with Von Hippel-Lindau syndrome, in certain
families the prevalence of pheochromocytoma can be more
than 90%. As a rule, all tumorous components of Von
Hippel-Lindau syndrome can be effectively treated if
diagnosed in time. Three paraganglioma syndrome predis-
position genes have been identified so far, namely, SDHB
the predisposition gene for PGL4, SDHC (PGL3), and SDHD
(PGL1). Patients with PGL1 nearly always display benign
but multiple adrenal pheochromocytomas and paraganglio-
mas of the head and neck. Patients with PGL4 often display
extra-adrenal, thoracic, or head-and-neck paragangliomas.
In contrast to PGL1, they are frequently malignant and
about one-third of patients develop metastases. PGL3 is not
associated with malignant pheochromocytoma/paragan-
glioma and patients display the characteristics of age,
manifestation, and tumor number similar to those with
sporadic HNPs. One has to be aware of the clinical
symptoms and signs that allow for an operational division,
which in turn is the cornerstone of prioritized genetic testing
and personalized management of patients and their
relatives (28). Hereditary pheochromocytoma and paragan-
glioma syndromes should be recognized as early as possible
in order to tailor medical management and follow-up.
Whereas the clinical and pathologic call of malignancy
remains a diagnostic challenge and preventive therapy
cannot be advised, it is key to conduct predictive testing of
as-yet-unaffected relatives, so that mutation carriers can
received a tailored screening and surveillance program (29).
Heritable non-medullary thyroid cancers
In contrast to heritable MTC, for which the genetic
differential diagnosis is straightforward and results in only
MEN 2, heritable non-MTC (NMTC) is more complex
(4,20,24,30). In this setting we have to differentiate between
NMTCs that are part of a heritable syndrome and those
that occur non-syndromically as familial NMTC. There are
three well-characterized syndromic forms of heritable
NMTC—Cowden syndrome, Gardner syndrome (familial
adenomatous polyposis syndrome), and Werner syndrome
— all of which are transmitted in an autosomal-dominant
fashion (31,32). Cowden syndrome is caused by germline
mutations of the PTEN tumor suppressor gene. Patients
with Cowden syndrome present with characteristic multi-
ple hamartomas and mucocutaneous lesions (e.g., oral
papillomatous papules, trichilemmoma, and acral kerato-
sis). In addition, affected patients are at high risk of
developing various benign and malignant neoplasias,
especially of the breast (up to 50% lifetime risk in affected
females) and thyroid gland. While benign thyroid nodules
are observed in up to 75% of patients, NMTC commonly
presents as a follicular thyroid carcinoma and is associated
with a 10-fold increased lifetime risk compared with the
general population.
Gardner syndrome is caused by germline mutations in the
APC gene and is characterized by gastrointestinal adeno-
matous polyps and a high risk of developing gastrointest-
inal and other cancers. It is estimated that the lifetime risk of
developing NMTC ranges between 2% and 10% in those
affected with familial adenomatous polyposis syndrome. In
contrast, the gastrointestinal manifestation will progress to
colorectal cancer in 100% of affected patients and preventive
surgery is advised for these patients. Interestingly, NMTC
will present in this setting as a unique pathologic variant
known as cribriform morular variant of papillary thyroid
carcinoma (33). Therefore, any patients with this diagnosis
who are operated on for thyroid disease should be screened
for familial adenomatous polyposis syndrome as well.
Werner syndrome is a rare autosomal recessive disease
that results in premature aging (34). Besides their elderly
appearance, affected patients develop various age-related
disorders such as diabetes, osteoporosis, heart disease, and
other malignancies. The latter two are responsible for a
diminished life expectancy of around 50 years. The
incidence of thyroid cancer (e.g., papillary, follicular, and
anaplastic thyroid cancer) is about 20%. Because of the
characteristic physical appearance, genetic testing is com-
monly used to confirm the clinical diagnosis.
Molecular diagnosis and predictive testing for these
syndromes are available and highly accurate, and the
results change medical management with regard to pro-
phylaxis and surveillance. What cannot be done currently is
accurately predict who will develop thyroid cancer and
what the age of maximal risk is. However, the high
incidence of malignant thyroid disease warrants regular
thyroid screening and a low threshold for recommending
thyroidectomy.
Table 3 - Comparison of pheochromocytoma-associated
and paraganglioma-associated syndromes.
Syndrome MEN2 VHL NF1 PGL1 PGL3 PGL4
Gene RET VHL NF1 SDHD SDHC SDHB
Mean age of diagnosis
(years)
36 22 41 27 46 34
Multifocal tumors +++ +++ ++ +++ + ++
Location
Adrenal +++ +++ +++ ++ – ++
Extra-adrenal – + – ++ – +++
HNP – – – ++ +++ +
Malignant ++ + + –– +++
+++: very high. ++: high. +: low. –: absent. HNP: head-and-neck
paraganglioma.
Modified from reference 7.
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94It has been suggested that there is an association between
non-MTC and two other familial cancer syndromes, Carney
complex (PRKAR1a) and Pendred syndrome. Based on a
small series of 15 kindreds with Carney complex the
prevalence of thyroid cancer is estimated 4% in affected
family members (35). For Pendred Syndrome the estimated
1% prevalence for thyroid cancer is deduced from a single
family report in which two of the three affected family
members developed follicular thyroid cancer (36). Whether
these are true associations due to the germline alterations that
areinvolved,orifadditionalmodifyingeventsparticipate,isa
matter of debate. However, patients with Carney complex
typicallydevelopnodularthyroid diseaseinchildhood(about
60%) and in Pendred syndrome there is a high frequency of
multinodular goiters and hypothyroidism. Hence, while a
preventive thyroidectomy cannot be advised for any of these
syndromes, a regular thyroid work-up should be part of the
routine surveillance for patients identified as being at risk.
Non-syndromic familial non-MTC
For non-syndromic familial NMTC (FNMTC), epidemio-
logic data indicate a very high likelihood of familial
aggregation and, hence, a strong genetic component (4,37).
Indeed, it is estimated that about 10% of all cases of NMTC
are hereditary, putting affected first-degree relatives at up to
a 10-fold increased risk compared with the general popula-
tion (38,39). In fact, differentiated epithelial thyroid carcino-
mas have one of the highest familial risks among all cancer
sites. FNMTC is characterized by two or more first-degree
relativeswho areaffected bythyroid carcinomas(NMTC)but
lack the signs of other hereditary syndromes or exposure to
other risk factors (e.g., radiation). This operational definition
is based on the assumption that the chance of clustering of
three or more relativeswith NMTCin onefamily bychance is
less than 6% (40). In contrast, there is a .60% likelihood that
two affected first-degree relatives will harbor sporadic
disease (40). The standardized incidence ratio is an index
that estimates the familial risk of developing a malignancy
based on epidemiologic data, and as a result may be viewed
as a measure of cancer risk for the children of parents with a
specific malignancy. For NMTC, the standardized incidence
ratio exceeds an impressive value of 3.8 (38,41). One might
argue that the familial aggregation might be the result of
environmental factors shared by the family members because
environmental factors have been implicated in thyroid
carcinogenesis. However, studies comparing cancer risk
between spouses showed that the standardized incidence
ratio does not exceed 1.4. Therefore, for NMTC, it has been
argued that heritability is most likely the main contributor to
the high standardized incidence ratios and that familial
aggregations of NMTC are most likely the result of germline
mutations in susceptibility genes.
Despite the impressive standardized incidence ratio for
FNMTC and tremendous efforts over the last 10 years to
identify the cancer-associated gene, no susceptibility genes
have been identified so far (4,42). Nevertheless, at least five
putative susceptibility loci have been identified. The caveat
remains that for each locus evidence both in favor and
opposing association with FNMTC has been published (42).
This can be explained by the fact that the operational definition
for FNMTC varies between studies (some already include
families with two affected first-degree relatives) and some
include benign thyroid diseases as well. Of the five loci on 1q21
(PRN),2q21 (NMTC1), 8p23.1-p22 (FTEN),14q31 (MNG1), and
19p13.2 (TCO), only TCO and NMTC1 have been replicated in
independent family sets, but the susceptibly genes mapped to
these loci have not been identified (42–46).
The NMTC1 locus has been replicated in 10 kindreds and
linkage to FNMTC is proposed with a logarithm of the odds
(LOD) score of 2.85 (where a LOD score .3 is accepted to
confirm linkage) is suggested (42). However, it has been
suggested that NMTC1 has a more significant association
with the follicular variant of papillary thyroid carcinoma. A
linkage between the TCO (thyroid tumors with cell
oxyphilia) locus and NMTC has been identified and
validated in four studies comprised of 21 families (LOD
score of 3.01) (42,43). In contrast, studies with a total of 65
relatives failed to show a linkage, so TCO might contribute
only slightly to FNMTC and be associated with cell
oxyphilia.
The MNG1 locus has only shown linkage (LOD score of
4.88) in one kindred with two family members who were
affected by papillary thyroid carcinoma. Interestingly, 18
family members showed multinodular goiters (44). Given
that six other studies that included .100 kindreds failed to
reproduce this association, MNG1 might rather account for a
familial form of benign nodular disease rather than FNMTC.
Linkage of the PRN locus (LOD score of 3.58) was
identified in one large kindred with five cases of papillary
thyroid carcinoma and two cases of papillary renal neoplasm
(45). However, no additional families have been identified so
far. Thus, the 1q21 locus might be associated with rare
phenotypes of papillary thyroid carcinoma and papillary
renal neoplasm. Recently, another association was identified
in one kindred with five cases of thyroid cancer and 11 cases
of benign nodular disease (47). The putative susceptibility
locus was mapped to 8q23.1-p22 with a LOD score of 4.41.
However, a follow-up study by the same group included six
families but failed to validate the linkage (48).
Thus, clinical genetic counseling or advice for families
segregating NMTC is imprecise. Notably, there is ongoing
debate as to whether or not FNMTC displays a more
aggressive phenotype compared with its sporadic counter-
part (49). Indeed, several studies have found that FNMTC
presents at a younger age and displays more aggressive
features, such as multifocality, local and lymph node
invasion, and diminished tumor-free and overall survival
rates (50–53). In contrast, other studies have failed to show a
difference between FNMTC and sporadic cancer (49,54,55). A
recent study that included 67 patients from 46 families with
FNMTC and 375 controls was not able to identify a more
aggressive phenotype (49,54). Still, there is a tendency for a
lower age of onset (42 vs. 47 years) in the FNMTC group
compared with the control group. Others have proposed
prophylactic thyroidectomy for FNMTC (42). However, from
a surgeon’s standpoint, the current data are too weak and
inconsistent for such a general demand. First and foremost
‘‘primum non nocere’’ has to prevail. Thus, in the setting of two
or more family members with NMTC, a thyroid work up
shouldbeoffered to all first-degree relativesand thepresence
of thyroid nodular disease should have a lower threshold for
recommending thyroidectomy to these patients.
KNOWING HERITABLE CANCER PHENOMICS: THE
FIRST STEP TO PRACTICE PERSONALIZED MEDICINE
Over the recent years, interest in the field of personalized
medicine has increased. In fact, one has to wonder if
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95personalized medicine is snowballing out of control when
direct-to-consumer genomic testing is becoming increasingly
available (56). Indeed, since 2007 the interested consumer is
able to receive a whole-genome scan for less than US$500,
withouteverhavingtoseea doctoror receivemedical advice.
This kind of self-administered genetic testing is problematic,
as shown by Bloss et al. (56) who found a correlation between
test-related distress and increased lifetime risk. Various
professional organizations, including the American Medical
Association and the American College of Medical Genetics,
state that such genetic testing should not be performed
without the supervision of healthcare providers. However,
centers for genomic medicine, and even clinical cancer
genetics, are far from being ubiquitously established even
in high-level medical centers. It is estimated that only 1% of
patients that would benefit from this 21st century approach
to medical treatment will be referred to professional genetic
counseling (31). The implementation of state-of-the-art
clinical genetic counseling within the constraints of budget
and limited human resources is one of the important tasks
that have to be tackled.
Eventually, one has to keep in mind that, notwithstanding
all of these technological advances, several tumor syn-
dromes can be identified by rigorous clinical analysis (57).
Especially regarding endocrine-related neoplasia, the med-
ical practitioner has to be aware of the phenomics, or
phenotypic profiles, that comes along with the array of
inheritable endocrine tumor syndromes. It is of no surprise
that several of the inherited tumor syndromes were first
described and named long before genetic causes had been
identified. In fact, it should be paramount to the medical
professional to use meticulous observation to ‘‘personalize’’
the decision for treatment options and, much more
importantly, to prioritize medical genetic testing.
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